Zhejiang Huahai Pharmaceutical Co Ltd
SSE:600521

Watchlist Manager
Zhejiang Huahai Pharmaceutical Co Ltd Logo
Zhejiang Huahai Pharmaceutical Co Ltd
SSE:600521
Watchlist
Price: 17.57 CNY 1.04% Market Closed
Market Cap: 25.5B CNY
Have any thoughts about
Zhejiang Huahai Pharmaceutical Co Ltd?
Write Note

Zhejiang Huahai Pharmaceutical Co Ltd
Cash

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Zhejiang Huahai Pharmaceutical Co Ltd
Cash Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash CAGR 3Y CAGR 5Y CAGR 10Y
Zhejiang Huahai Pharmaceutical Co Ltd
SSE:600521
Cash
ÂĄ1.5B
CAGR 3-Years
2 164%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Cash
ÂĄ22.4B
CAGR 3-Years
74%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Cash
ÂĄ8.8B
CAGR 3-Years
59%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Cash
ÂĄ22.3B
CAGR 3-Years
16%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Yunnan Baiyao Group Co Ltd
SZSE:000538
Cash
ÂĄ14.1B
CAGR 3-Years
2%
CAGR 5-Years
N/A
CAGR 10-Years
160%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Cash
ÂĄ391.7m
CAGR 3-Years
1 693%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Zhejiang Huahai Pharmaceutical Co Ltd
Glance View

Market Cap
25.8B CNY
Industry
Pharmaceuticals

Zhejiang Huahai Pharmaceutical Co. Ltd. engages in the manufacture and sale of pharmaceutical products. The company is headquartered in Taizhou, Zhejiang and currently employs 7,019 full-time employees. The company went IPO on 2003-03-04. The firm's main products are classified as -pril series, -sartan series and preparations, including irbesartan tablets, paroxetine hydrochloride tablets, risperidone tablets, fosinopril sodium tablets, as well as irbesartan and hydrochlorothinzide tablets, among others. The firm also provides related technical support services. The firm distributes its products in domestic and overseas markets.

Intrinsic Value
25.58 CNY
Undervaluation 31%
Intrinsic Value
Price

See Also

What is Zhejiang Huahai Pharmaceutical Co Ltd's Cash?
Cash
1.5B CNY

Based on the financial report for Jun 30, 2024, Zhejiang Huahai Pharmaceutical Co Ltd's Cash amounts to 1.5B CNY.

What is Zhejiang Huahai Pharmaceutical Co Ltd's Cash growth rate?
Cash CAGR 3Y
2 164%

Over the last year, the Cash growth was -19%. The average annual Cash growth rates for Zhejiang Huahai Pharmaceutical Co Ltd have been 2 164% over the past three years .

Back to Top